EUCTR2008-005825-12-IT进行中（未招募）不适用
: A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme) Enzyme Replacement Therapy - PB-06-002
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Males and females, 18 years or older
- •Female patients of child-bearing potential and male patients with female partners of child-bearing potential must agree to use a medically acceptable method of contraception, not including the rhythm method
- •Diagnosis of Gaucher disease with leukocyte GCD activity level ≤3 nmol/mg*hr (≤30 % of the mean activity of the reference range)
- •Stable Gaucher disease, defined as:
- •a.Hemoglobin during Stability Evaluation Period is stable with no value more than 15% below or above the mean value
- •b.Platelets count during Stability Evaluation Period is stable with no values more than 40% below or above the mean value if the mean value is >120,000, or more than 20% below or above the mean value if the mean value is ≤ 120,000
- •c.No major surgery in the last year
- •d.No blood transfusion or major bleeding episode in the last year
- •e.No acute avascular necrosis event in the last year
- •f.No evidence of spleen or liver increasing enlargement while being treated with enzyme replacement therapy by palpation, ultrasound, or MRI over the last year
- •Receiving imiglucerase therapy for at least 2 years and on a stable maintenance regimen (dose unchanged) for at least last six months
- •Able to provide written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Currently taking another experimental drug for any condition
- •Pregnant or nursing or planning to become pregnant
- •History of allergy to carrots
- •Presence of anti-glucocerebrosidase (GCD) antibodies
- •Previous infusion reaction suspected to be allergic in nature to Cerezym or Ceredase or receiving premedication to prevent infusion reactions
- •Presence of HIV and/or HBsAg and/or hepatitis C infection
- •Presence of unresolved anemia due to iron, folic acid or vitamin B12 deficiency
- •Presence of any significant comorbidity that could confound the interpretation of the clinical response to prGCD
- •Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patients compliance with the requirements of the study.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme®) Enzyme Replacement Therapy - NAMedDRA version: 9.1 Level: PT Classification code 10018048 Term: Gaucher's diseaseGaucher DiseaseEUCTR2008-005825-12-GBProtalix Biotherapeutics30
进行中（未招募）
不适用
A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated with Imiglucerase (Cerezyme®) Enzyme Replacement Therapy - NAGaucher DiseaseMedDRA version: 9.1Level: PTClassification code 10018048Term: Gaucher's diseaseEUCTR2008-005825-12-DEProtalix Biotherapeutics30
进行中（未招募）
1 期
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year old Healthy Children who Previously Participated in Study V72P12E1Prevention of meningococcal disease caused by serogroup B Neisseria meningitidis by evaluating the Antibody persistence in 4-year old healthy children who previously received the Novartis meningococcal B Recombinant vaccine (rMenB+OMV NZ) as infants in study V72P12 and received a booster dose in study V72P12E1 and characterizing the antibody response to a fifth or a third booster dose or two catch-up doses of the rMenB+OMV NZ vaccine at 4 years of age.EUCTR2011-004931-30-GBovartis Vaccines and Diagnostics S.r.l.805
进行中（未招募）
不适用
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year old Healthy Children who Previously Participated in Study V72P12E1Prevention of meningococcal disease caused by serogroup B Neisseria meningitidis by evaluating the Antibody persistence in 4-year old healthy children who previously received the Novartis meningococcal B Recombinant vaccine (rMenB+OMV NZ) as infants in study V72P12 and received a booster dose in study V72P12E1 and characterizing the antibody response to a fifth or a third booster dose or two catch-up doses of the rMenB+OMV NZ vaccine at 4 years of age.MedDRA version: 16.1Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-004931-30-CZovartis Vaccines and Diagnostics S.r.l.1,700
进行中（未招募）
不适用
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year old Healthy Children who Previously Participated in Study V72P12E1EUCTR2011-004931-30-ESovartis Vaccines and Diagnostics S.r.l.1,560